Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | NAALAD2 | Q9Y3Q0 | 6/20 | 0.55 |
| ▸ | GGH | Q92820 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.52 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CPA3 | P15088 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60370 | 1.00 | GAA (0.62) | GAANAALAD2GGHMMP9MMP8 | |
| SCHEMBL16402636 | 0.89 | GAA (0.51) | GAANAALAD2GGHMMP9MMP8 | |
| SCHEMBL3448327 | 0.86 | KMT2A (0.64) | GAANAALAD2GGHMMP9MMP8 | |
| SCHEMBL30818291 | 0.86 | GAA (0.48) | GAANAALAD2GGHMMP9MMP8 | |
| SCHEMBL3448329 | 0.86 | KMT2A (0.64) | GAANAALAD2GGHMMP9MMP8 | |
| SCHEMBL4821017 | 0.86 | GAA (0.51) | GAANAALAD2GGHMMP9MMP8 | |
| Hydrochloric Acid SCHEMBL23834278 | 0.84 | KMT2A (0.62) | GAANAALAD2GGHMMP9MMP8 | |
| SCHEMBL5497952 | 0.84 | FOLH1 (0.59) | GAAGGHFOLH1 | |
| SCHEMBL11835127 | 0.84 | GGH (0.48) | GAANAALAD2GGHMMP9MMP8 | |
| SCHEMBL28535426 | 0.84 | GGH (0.48) | GAANAALAD2GGHMMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129092-B2 | Resist pattern thickening material and process for forming resist pattern, and semiconductor device and method for manufacturing the same | FUJITSU LIMITED (JP) | 2012-03-06 | — | — | US | claimed |
| CN-1975571-B | Resist pattern thickening material and process for forming resist pattern, and semiconductor device and method for manufacturing the same | FUJITSU LTD | 2011-04-06 | — | — | CN | claimed |
| US-20240025946-A1 | Cyclic Tetrapeptides and Metal Complexes Thereof | Universität Zürich (CH) | 2024-01-25 | — | — | US | disclosed |
| US-11124520-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibitor and antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200181152-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2020-06-11 | — | — | US | disclosed |
| US-10538527-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-01-21 | — | — | US | disclosed |
| US-20190241571-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2019-08-08 | — | — | US | disclosed |
| US-10239880-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-03-26 | — | — | US | disclosed |
| US-20160304525-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2016-10-20 | — | — | US | disclosed |
| WO-2016168637-A2 | CYCLOPENTA[D]PYRIMIDINES AND SUBSTITUTED CYCLOPENTA[D]PYRIMIDINES AS ANTITUBULIN AND MICROTUBULE TARGETING AGENTS, MONOCYCLIC PYRIMIDINES AS TUBULIN INHIBITORS, AND PYRROLOPYRIMIDINES AS TARGETED ANTIFOLATES AND TUBULIN AND MULTIPLE RECEPTOR TYROSINE KINASE INHIBITION AND ANTITUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2016-10-20 | — | — | WO | disclosed |
| US-8906598-B2 | Pattern forming method, method for manufacturing semiconductor device, and material for forming coating layer of resist pattern | FUJITSU LIMITED (JP) | 2014-12-09 | — | — | US | disclosed |
| EP-1793274-A2 | Resist pattern thickening material and process for forming resist pattern, and semiconductor device and method for manufacturing the same | FUJITSU LIMITED (JP) | 2007-06-06 | — | — | EP | disclosed |
| CN-1975571-A | Resist pattern thickening material and process for forming resist pattern, and semiconductor device and method for manufacturing the same | FUJITSU LTD (JP) | 2007-06-06 | — | — | CN | disclosed |
| US-20070123623-A1 | Resist pattern thickening material and process for forming resist pattern, and semiconductor device and method for manufacturing the same | FUJITSU LIMITED (JP) | 2007-05-31 | — | — | US | disclosed |
| WO-2006102594-A1 | NUCLEOSIDE PRODRUGS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| EP-1656387-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005012324-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| CN-1468095-A | Colloidal suspension of submicronic particles for carrying hydrophilic active principles (insulin) and method for preparing same | ÷ | 2004-01-14 | — | — | CN | disclosed |
| EP-1228083-A2 | THERAPEUTIC TREATMENT OF ANDROGEN RECEPTOR DRIVEN CONDITIONS | Hollis-Eden Pharmaceuticals Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001023405-A2 | THERAPEUTIC TREATMENT OF ANDROGEN RECEPTOR DRIVEN CONDITIONS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304525-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | FOLR1, TUBB1, TUBA1C | GAA 3877/4885NAALAD2 3670/4885GGH 1961/4885 |
| US-20200181152-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | FOLR1, DHFR, TUBB3 | GAA 3538/4885NAALAD2 3067/4885GGH 1852/4885 |
| US-20190241571-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | TUBB, TUBB1, TUBA1C | GAA 4099/4885NAALAD2 2929/4885GGH 2606/4885 |
| US-20240025946-A1 | Cyclic Tetrapeptides and Metal Complexes Thereof | VIP, PTMS, PEPD | GAA 358/4885NAALAD2 151/4885GGH 106/4885 |
| US-10239880-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | FOLR1, TUBB1, TUBA1C | GAA 3877/4885NAALAD2 3670/4885GGH 1961/4885 |
| US-11124520-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibitor and antitumor agents | FOLR1, DHFR, TUBB3 | GAA 3550/4885NAALAD2 3058/4885GGH 1860/4885 |
| US-10538527-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | TUBB, TUBB1, TUBA1C | GAA 4099/4885NAALAD2 2929/4885GGH 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.